Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHA

<p class="MsoNormal">Featuring an interview with Dr Eunice S Wang, including the following topics:</p> <ul> <li>Hypomethylating agent/venetoclax combinations for the treatment of acute myeloid leukemia (AML); integration in community practice (0:00)</li> <li>All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed AML not eligible for intensive induction chemotherapy (9:39)</li> <li>Efficacy of targeted therapy options for AML; potential role of MRD (minimal residual disease) assays in monitoring treatment response (13:07)</li> <li>Treatment approach for patients with FLT3-mutant AML; mutation profiles and predicting response to quizartinib (20:14)</li> <li>Targeting the differentiation of AML tumor cells with IDH and menin inhibitors; associated differentiation syndrome (29:24)</li> <li>Efficacy and tolerability of the IDH inhibitors ivosidenib and olutasidenib (36:54)</li> <li>Key clinical data with approved and investigational menin inhibitors fo...